Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 6 pages · Chinese
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
- Voluntary Disclosure Announcement on the Release of the Latest Research Results of DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Conference
- Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
- Announcement on Result of Share Reduction by Director and Senior Management Member
- 2024 Annual Report
Later from Dizal (Jiangsu) Pharmaceutical
- Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
- Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
- Announcement on the Listing and Circulation of Some Restricted Shares in Initial Public Offering
- Announcement on Share Reduction Plan for Senior Management Members
- Announcement on Release of Pledge of Partial Shares of Shareholder
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical